相关临床试验
19
17 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
17
89.5%
已完成
1
5.3%
招募中
1
5.3%
暂无批准数据
- An eye surgeon reports fewer people sought treatment for eye damage after the UK's recent solar eclipse compared with the 1999 total eclipse. - Millions across the UK witnessed the most significant solar eclipse in 27 years, with more than 90% of the Sun covered by the Moon. - Mr Alexander Ionides of Moorfields Eye Hospital said public warnings about looking directly at the Sun appear to be "getting through." - Symptoms of solar eye damage can include a grey or yellow spot in the centre of vision, developing within hours or sometimes days.
- A six-year-old girl with Leber's Congenital Amaurosis has had her vision restored through Luxturna gene therapy, marking the first treatment of its kind on the NHS for this genetic cause of blindness. - New research from Great Ormond Street Hospital and UCL demonstrates that Luxturna can strengthen visual pathways during critical brain development periods in young children with RPE65-related retinal disease. - The study of 15 children treated between 2020 and 2023 shows that younger patients experience greater improvement when treated during critical visual development periods. - Pattern visual evoked potentials (VEPs) emerged as a new objective assessment tool for measuring gene therapy effectiveness in pediatric patients with inherited retinal diseases.
- MeiraGTx has entered into an asset purchase agreement with Johnson & Johnson to reacquire botaretigene sparoparvovec (bota-vec) for treating X-linked retinitis pigmentosa, paying $25 million upfront plus milestone payments and royalties. - The Phase 3 LUMEOS trial demonstrated statistically significant improvements across multiple vision domains, with 45% of treated patients gaining more than 10 letters in low luminance visual acuity and 40% showing improvement in two or more endpoints. - MeiraGTx plans to file for regulatory approval in the U.S., EU, and Japan immediately, targeting a potential commercial launch in 2027 for a disease affecting over 20,000 patients with no current treatment options. - The company has already completed manufacturing process qualification and holds commercial licenses for its London manufacturing facility, positioning it to supply patients immediately upon regulatory approval.
- A groundbreaking gene therapy developed by Moorfields Eye Hospital and MeiraGTx has successfully restored vision in children born with LCA-AIPL1, a severe inherited eye disorder affecting 2-3 in 10 million newborns. - Clinical trials demonstrated significant vision improvement in all eleven treated children, with some achieving 20/80 vision, enabling them to identify pictures, safely navigate, and engage in visual activities for the first time. - The treatment must be administered before age four due to irreversible retinal degeneration, with regulatory approval expected within 1-2 years following successful safety and efficacy demonstrations.
